Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04775537 · ClinicalTrials.gov registry record

OssiMend BA in Posterolateral Instrumented Lumbar Fusion

A clinical trial of Degenerative Disc Disease and Spinal Disease, sponsored by Collagen Matrix.

Recruiting
Registry status
120
Enrollment target
4
Study locations

NCT04775537 is a study of Degenerative Disc Disease and Spinal Disease that is actively recruiting participants, run by Collagen Matrix. The registered enrollment target is 120 participants, below the 166-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (28% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04775537, a study of Degenerative Disc Disease and Spinal Disease, is actively recruiting participants, sponsored by Collagen Matrix.

RECRUITING
Registry status
120 participants
Enrollment target
4
Study locations

Study Summary

The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material

Interventions

  • DEVICE OssiMend™ Bioactive Moldable

Study Locations (4)

California

  • San Diego Neurosurgery - Encinitas

Connecticut

  • Hartford Hospital - Hartford

New Jersey

  • University Orthopaedic Associates, Division of OrthoNJ - Somerset

Oregon

  • McKenzie-willamette Medical Center - Eugene

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2021-01-21
Est. Completion 2027-01-30

Sponsor

Collagen Matrix

5 total trials

What the Registry Record Tells You About NCT04775537

The ClinicalTrials.gov registry entry for NCT04775537 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 166-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (28% lower). The listed sponsor is Collagen Matrix, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Degenerative Disc Disease appearing as the primary indexed condition, and to 1 intervention - of which OssiMend™ Bioactive Moldable is the first listed.

NCT04775537 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Connecticut, New Jersey.

Frequently Asked Questions

What is clinical trial NCT04775537 about?

NCT04775537 is a clinical study titled "OssiMend BA in Posterolateral Instrumented Lumbar Fusion". The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material

What is the current status of trial NCT04775537?

This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2021-01-21. Estimated completion is 2027-01-30.

What conditions does trial NCT04775537 study?

This clinical trial studies the following conditions: Degenerative Disc Disease, Spinal Disease.

What interventions are being tested in trial NCT04775537?

The interventions under investigation include: OssiMend™ Bioactive Moldable (DEVICE).

Who is sponsoring clinical trial NCT04775537?

This trial is sponsored by Collagen Matrix, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04775537 being conducted?

This trial has 4 study locations across California, Connecticut, New Jersey, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Degenerative Disc Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.